These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 39363355)

  • 1. Different diseases, different needs: Patient preferences for gene therapy in lysosomal storage disorders, a probabilistic threshold technique survey.
    Corazolla EM; Eskes ECB; Veldwijk J; Brands MMMG; Dekker H; van de Mheen E; Langeveld M; Hollak CEM; Sjouke B
    Orphanet J Rare Dis; 2024 Oct; 19(1):367. PubMed ID: 39363355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients' view on gene therapy development for lysosomal storage disorders: a qualitative study.
    Eskes ECB; Beishuizen CRL; Corazolla EM; van Middelaar T; Brands MMMG; Dekker H; van de Mheen E; Langeveld M; Hollak CEM; Sjouke B
    Orphanet J Rare Dis; 2022 Oct; 17(1):383. PubMed ID: 36271424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New prospects for the treatment of lysosomal storage diseases.
    Schiffmann R; Brady RO
    Drugs; 2002; 62(5):733-42. PubMed ID: 11929328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatable lysosomal storage diseases in the advent of disease-specific therapy.
    Peters H; Ellaway C; Nicholls K; Reardon K; Szer J
    Intern Med J; 2020 Nov; 50 Suppl 4():5-27. PubMed ID: 33210402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: A nationwide survey in Japan.
    Koto Y; Sakai N; Lee Y; Kakee N; Matsuda J; Tsuboi K; Shimozawa N; Okuyama T; Nakamura K; Narita A; Kobayashi H; Uehara R; Nakamura Y; Kato K; Eto Y
    Mol Genet Metab; 2021 Jul; 133(3):277-288. PubMed ID: 34090759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The patient journey of patients with Fabry disease, Gaucher disease and Mucopolysaccharidosis type II: A German-wide telephone survey.
    Mengel E; Gaedeke J; Gothe H; Krupka S; Lachmann A; Reinke J; Ohlmeier C
    PLoS One; 2020; 15(12):e0244279. PubMed ID: 33382737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gaucher and Fabry diseases: from understanding pathophysiology to rational therapies.
    Brady RO
    Acta Paediatr Suppl; 2003 Dec; 92(443):19-24. PubMed ID: 14989461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: A state-of-the art review.
    Jezela-Stanek A; Chorostowska-Wynimko J; Tylki-Szymańska A
    Clin Respir J; 2020 May; 14(5):422-429. PubMed ID: 31912638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fetal therapies and trials for lysosomal storage diseases: a survey of attitudes of parents and patients.
    Schwab ME; Brown JEH; Lianoglou B; Jin C; Conroy PC; Gallagher RC; Harmatz P; MacKenzie TC
    Orphanet J Rare Dis; 2022 Jan; 17(1):25. PubMed ID: 35093147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lysosomes and lysosomal storage diseases].
    Germain DP
    J Soc Biol; 2002; 196(2):127-34. PubMed ID: 12360741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide.
    Mehta A; Ramaswami U; Muenzer J; Giugliani R; Ullrich K; Collin-Histed T; Panahloo Z; Wellhoefer H; Frader J
    Orphanet J Rare Dis; 2021 Jan; 16(1):8. PubMed ID: 33407729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gaucher disease, Fabry disease and mucopolysaccharidosis type I--how can the rheumatologist recognise these patients?].
    Manger B; Menge E; Schaefer R; Haase C; Seidel J; Michels H
    Z Rheumatol; 2006 Feb; 65(1):32, 34-43. PubMed ID: 16467949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysosomal storage disorders: Novel and frequent pathogenic variants in a large cohort of Indian patients of Pompe, Fabry, Gaucher and Hurler disease.
    Thomas DC; Sharma S; Puri RD; Verma IC; Verma J
    Clin Biochem; 2021 Mar; 89():14-37. PubMed ID: 33301762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease.
    Sawkar AR; D'Haeze W; Kelly JW
    Cell Mol Life Sci; 2006 May; 63(10):1179-92. PubMed ID: 16568247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy for the lysosomal storage disorders.
    Cabrera-Salazar MA; Novelli E; Barranger JA
    Curr Opin Mol Ther; 2002 Aug; 4(4):349-58. PubMed ID: 12222873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opinions of adults affected with later-onset lysosomal storage diseases regarding newborn screening: A qualitative study.
    Lisi EC; Ali N
    J Genet Couns; 2021 Dec; 30(6):1544-1558. PubMed ID: 33938615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
    Fabrega S; Lehn P
    J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
    Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
    Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.